Eli Lilly and Company (NYSE:LLY) Given New $892.00 Price Target at Truist Financial

Eli Lilly and Company (NYSE:LLY) had its price target hoisted by Truist Financial from $850.00 to $892.00 in a research note issued to investors on Wednesday, Benzinga reports. Truist Financial currently has a buy rating on the stock.

A number of other analysts have also recently weighed in on the company. DZ Bank cut Eli Lilly and Company from a buy rating to a hold rating and set a $820.00 price target on the stock. in a research report on Wednesday, February 21st. Cantor Fitzgerald restated an overweight rating and issued a $885.00 target price (up previously from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday. Bank of America boosted their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a buy rating in a research report on Friday, March 1st. The Goldman Sachs Group lifted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a neutral rating in a research note on Thursday, April 11th. Finally, Barclays increased their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an overweight rating in a research note on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus target price of $757.95.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $776.75 on Wednesday. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The company has a market capitalization of $738.04 billion, a price-to-earnings ratio of 114.40, a price-to-earnings-growth ratio of 1.58 and a beta of 0.37. Eli Lilly and Company has a twelve month low of $399.26 and a twelve month high of $800.78. The business has a 50 day simple moving average of $762.03 and a 200-day simple moving average of $669.96.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 59.28%. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same quarter in the previous year, the firm earned $1.62 earnings per share. The firm’s revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, equities research analysts expect that Eli Lilly and Company will post 13.5 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Lipe & Dalton purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at $26,000. Thompson Investment Management Inc. purchased a new position in Eli Lilly and Company in the third quarter valued at about $27,000. Tidemark LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $29,000. Core Wealth Advisors Inc. increased its holdings in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares during the last quarter. Finally, Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $35,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.